Skip to main navigation Skip to search Skip to main content

Risk factors and outcomes of posterior reversible encephalopathy syndrome in systemic lupus erythematosus: a retrospective-multicentre cohort study and systematic literature review

  • Ali Ardekani
  • , Alain Sanchez-Rodriguez
  • , Mariana Gonzalez-Treviño
  • , Jose A. Meade-Aguilar
  • , Maria O. Valenzuela-Almada
  • , Hannah E. Langenfeld
  • , Larry J. Prokop
  • , Isabel Valenzuela-Almada
  • , Gabriel Figueroa-Parra
  • , Nicolás Sánchez Domínguez
  • , Alejandro A. Rabinstein
  • , Mohammad Hassan Murad
  • , Cynthia S. Crowson
  • , Ali Duarte-Garcia

Research output: Contribution to journal › Review article › peer-review

Abstract

Objective Posterior reversible encephalopathy syndrome (PRES) is a clinicoradiological diagnosis that can be associated with SLE. The clinical presentation, risk factors and outcomes of PRES in patients with SLE remain insufficiently described. Methods We conducted a multicentre cohort study at the Mayo Clinic and performed a systematic literature review (SLR) of patients with incident PRES and SLE. We described the clinical features, treatments and outcomes. Across both the cohort study and SLR, we assessed neurological sequelae, recurrence and survival. Within the cohort study, we examined PRES risk factors and discontinuation of antiseizure medications (ASMs). We used logistic regression to evaluate factors associated with neurological sequelae and Cox regression to assess predictors of recurrence. Kaplan-Meier methods estimated the rates of recurrence, survival and ASMs discontinuation. Results 550 cases (53 from the cohort study) were included, of whom 92% were female. Across both cohort and SLR, the most common symptom was seizure, occurring in 80%. PRES was the first manifestation of SLE in 13% of cases. In the adjusted analysis, older age was associated with neurological sequelae (OR 1.63 per 10-year increase; 95%CI 1.12 to 2.39). After 5 years of follow-up, 11.5% (95% CI 2.3 to 19.9%) of patients had a recurrent PRES episode. 30-day and 180-day survival following PRES was observed in 96.3% (95% CI 93.5 to 99.1%) and 93.7% (95% CI 89.8 to 97.7%) patients, respectively. In the Mayo Clinic cohort, 81% of PRES cases were attributed to hypertension in the context of lupus nephritis (LN), and by the fifth year of follow-up, 78.1% (95% CI 58.7 to 88.4%) of patients had discontinued ASMs. Conclusions In this cohort, most of the incident PRES episodes were preceded by hypertension and occurred in patients with LN. Although short-term and long-term prognoses are favourable, older patients more frequently experienced neurological sequelae.

Original languageEnglish (US)
Article numbere001780
JournalLupus Science and Medicine
Volume12
Issue number2
DOIs
StatePublished - Dec 11 2025

Keywords

  • Lupus Erythematosus, Systemic
  • Lupus Nephritis
  • Risk Factors
  • Systematic Review

ASJC Scopus subject areas

  • Rheumatology
  • Immunology

Fingerprint

Dive into the research topics of 'Risk factors and outcomes of posterior reversible encephalopathy syndrome in systemic lupus erythematosus: a retrospective-multicentre cohort study and systematic literature review'. Together they form a unique fingerprint.

Cite this